NTLA Intellia Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1652130 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.1%
TTM net income YoY4.4%
TTM EPS YoY21.2%
Revenue 3-yr CAGR77.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-821.2%
Net margin-805.7%
FCF margin-677.1%
EBITDA margin-805.0%
Returns
ROE-62.6%
ROA-46.6%
ROIC (approx.)-63.2%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.12x
Current ratio6.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $67.67M | $57.88M | $6.60M | $11.40M | $2.90M |
| Cost of revenue | — | — | — | — | $0 |
| Gross profit | — | — | — | — | $2.90M |
| R&D expense | $388.86M | $466.31M | $435.07M | $419.98M | $229.81M |
| SG&A expense | $119.80M | $125.83M | $116.50M | $90.31M | $71.10M |
| Operating income | -$440.99M | -$534.26M | -$515.29M | -$458.16M | -$267.85M |
| Income tax | $0 | — | — | — | — |
| Net income | -$412.69M | -$519.02M | -$481.19M | -$474.19M | -$267.89M |
| EBITDA | -$431.22M | -$523.98M | -$506.31M | -$450.59M | -$260.96M |
| EPS (basic) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 |
| EPS (diluted) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 |
| Weighted avg. shares (diluted) | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M |
| Balance sheet | |||||
| Cash & equivalents | $155.46M | $189.18M | $226.75M | $523.51M | $123.41M |
| Short-term investments | $294.42M | $412.33M | $685.48M | $669.12M | $625.28M |
| Receivables | $9.47M | $8.52M | $36.46M | $3.77M | $2.03M |
| Current assets | $527.71M | $639.86M | $998.33M | $1.22B | $769.30M |
| PP&E, net | $17.67M | $27.38M | $32.76M | $27.92M | $20.97M |
| Total assets | $842.13M | $1.19B | $1.30B | $1.52B | $1.29B |
| Current liabilities | $103.88M | $110.85M | $115.21M | $126.55M | $125.83M |
| Long-term debt | $0 | — | — | — | — |
| Total debt | $0 | — | — | — | — |
| Total liabilities | $170.73M | $319.06M | $250.81M | $284.53M | $254.22M |
| Shareholders' equity | $671.39M | $871.96M | $1.05B | $1.24B | $1.04B |
| Net debt | -$155.46M | — | — | — | — |
| Shares outstanding | 116.32M | 102.03M | 93.00M | 87.10M | 74.49M |
| Cash flow statement | |||||
| Operating cash flow | -$394.74M | -$348.88M | -$394.09M | -$333.29M | -$225.03M |
| Capital expenditure | $1.13M | $5.78M | $13.98M | $13.56M | $12.76M |
| Free cash flow | -$395.87M | -$354.66M | -$408.07M | -$346.85M | -$237.79M |
| Investing cash flow | $228.03M | $125.57M | -$31.35M | $160.31M | -$550.78M |
| Financing cash flow | $131.49M | $185.75M | $130.32M | $582.96M | $736.69M |
| Depreciation & amortization | $9.77M | $10.29M | $8.98M | $7.57M | $6.89M |
| Stock-based compensation | $80.22M | $154.27M | $134.05M | $91.40M | $47.01M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.